It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARQT’s FA Score shows that 0 FA rating(s) are green whileARWR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARQT’s TA Score shows that 5 TA indicator(s) are bullish while ARWR’s TA Score has 4 bullish TA indicator(s).
ARQT (@Biotechnology) experienced а +3.12% price change this week, while ARWR (@Biotechnology) price change was -14.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.
ARQT is expected to report earnings on Mar 04, 2025.
ARWR is expected to report earnings on Feb 05, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ARQT | ARWR | ARQT / ARWR | |
Capitalization | 1.2B | 2.27B | 53% |
EBITDA | -163.28M | -508.26M | 32% |
Gain YTD | 217.028 | -40.261 | -539% |
P/E Ratio | N/A | N/A | - |
Revenue | 139M | 19.6M | 709% |
Total Cash | 331M | 434M | 76% |
Total Debt | 208M | 118M | 176% |
ARWR | ||
---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 83 | |
P/E GROWTH RATING 1..100 | 2 | |
SEASONALITY SCORE 1..100 | 95 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARQT | ARWR | |
---|---|---|
RSI ODDS (%) | 1 day ago88% | 1 day ago77% |
Stochastic ODDS (%) | 1 day ago90% | 1 day ago71% |
Momentum ODDS (%) | 1 day ago90% | 1 day ago86% |
MACD ODDS (%) | 1 day ago75% | 1 day ago85% |
TrendWeek ODDS (%) | 1 day ago83% | 1 day ago84% |
TrendMonth ODDS (%) | 1 day ago81% | 1 day ago83% |
Advances ODDS (%) | 1 day ago83% | 12 days ago78% |
Declines ODDS (%) | 8 days ago90% | 8 days ago83% |
BollingerBands ODDS (%) | 1 day ago90% | 1 day ago84% |
Aroon ODDS (%) | 1 day ago86% | 1 day ago68% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
EATVX | 44.07 | 0.44 | +1.01% |
Eaton Vance Tx-Mgd Value A | |||
EAFVX | 22.19 | 0.22 | +1.00% |
Eaton Vance Focused Value Opps A | |||
PRKZX | 8.08 | 0.05 | +0.62% |
PGIM Real Estate Income Z | |||
MLACX | 6.40 | 0.02 | +0.31% |
NYLI Winslow Large Cap Growth Class C | |||
PIEIX | 26.09 | -0.10 | -0.38% |
Principal Glb Emerging Markets Inst |
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with BEAM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then BEAM could also see price increases.
Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
---|---|---|---|---|
ARQT | 100% | +0.59% | ||
BEAM - ARQT | 39% Loosely correlated | -3.72% | ||
ARWR - ARQT | 37% Loosely correlated | -2.30% | ||
PLRX - ARQT | 37% Loosely correlated | +0.94% | ||
SANA - ARQT | 36% Loosely correlated | -7.11% | ||
RXRX - ARQT | 36% Loosely correlated | -4.80% | ||
More |
A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To ARWR | 1D Price Change % | ||
---|---|---|---|---|
ARWR | 100% | -2.30% | ||
NTLA - ARWR | 50% Loosely correlated | +5.18% | ||
CRNX - ARWR | 48% Loosely correlated | +1.71% | ||
EDIT - ARWR | 47% Loosely correlated | -1.66% | ||
BEAM - ARWR | 46% Loosely correlated | -3.72% | ||
ALNY - ARWR | 46% Loosely correlated | -0.80% | ||
More |